Abiopharma

🔍 OConnell Daniel Joseph (Director)

Company: Acumen Pharmaceuticals, Inc. (ABOS)

Report Date: 2026-01-05

Detailed Transactions and Holdings:

• Sold 4,649 shares of Common Stock at $1.971 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 662,839.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 5,102 shares of Common Stock at $1.9662 per share (Direct)
  Date: 2026-01-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 657,737.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 37,755 shares of Common Stock at $1.986 per share (Direct)
  Date: 2026-01-07 | Code: S | equity_swap_involved: 0 | shares_owned_after: 619,982.00 | transaction_form_type: 4 | Footnotes: F1, F4

Footnotes:

• F1: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2024.
• F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9000 to $2.0600. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9400 to $2.0000. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F4: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9500 to $2.0300. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.